Overview
A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).
Eligibility
Inclusion Criteria:
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL
- Relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available.
- At least one evaluable or measurable lesion (as defined in the protocol).
- ECOG Performance Status 0 or 1.
- Life expectancy ≥12 weeks.
- Adequate organ function (as defined in the protocol).
- Reproductive criteria (as defined in the protocol).
Exclusion Criteria:
- Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption.
- Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
- Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
- Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose.
- History of a second malignancy within 2 years (as defined in the protocol).
- Active uncontrolled or symptomatic lung disease (as defined in the protocol).
- Intracranial hypertension or active uncontrolled or symptomatic CNS metastases.
- Known or suspected hypersensitivity to study medications.
- Known active uncontrolled or symptomatic CNS metastases.
- The investigator determined that the patient should not participate in the study.
- Known mental illness or substance abuse that may disrupt therapy.
- Clinically significant cardiac abnormalities (as defined in the protocol).
- Gestating or Lactating women.
- Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose.
- The patient is currently using a drug known to be a strong inhibitor or inducer of CYP3A4.